Navigation Links
ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe
Date:2/27/2008

SALT LAKE CITY, Feb. 27 /PRNewswire/ -- ZARS Pharma, Inc. announced today that Rapydan(R) (70 mg lidocaine/70 mg tetracaine medicated plaster) has now received marketing authorization in Sweden, the United Kingdom, the Netherlands, France, Spain, Austria, the Czech Republic, Greece, Ireland, Norway and Portugal following the completion of the European Mutual Recognition Procedure. ZARS Pharma has licensed the European sales and marketing rights of Rapydan to EUSA Pharma, Inc. Rapydan received marketing authorization in Sweden in January 2007 and was launched in May 2007. EUSA Pharma began launching Rapydan in other European Union countries in early 2008.

Rapydan is a topical local anesthetic patch approved for use on normal and intact skin to provide surface anesthesia of the skin in connection with needle punctures, in children from 3 years and above, and needle punctures and superficial surgical procedures in adults. Rapydan resembles a small adhesive bandage in appearance and is similar in its ease of application. The patch is applied to the skin for 30 minutes before painful medical procedures. Rapydan is the first product approved in Europe using the patented Controlled Heat-Assisted Drug Delivery or CHADD(R) technology developed by ZARS Pharma.

Rapydan is marketed as Synera(R) (lidocaine 70 mg and tetracaine 70 mg) in the United States and was approved by the U.S. Food and Drug Administration in 2005.

Robert Lippert, President and Chief Executive of ZARS Pharma stated, "We are pleased to announce the approval of Rapydan in a number of European Union countries with a uniquely positioned commercial partner. Rapydan is the first anesthetic patch innovation to be approved in over a decade that works faster than the current standard of care and will soon become a best-in-class therapy for patients undergoing painful needle procedures."

About Rapydan

Rapydan is comprised of a thin layer of a patented local anesthetic formula
'/>"/>

SOURCE ZARS Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... and BANGALORE, India , ... genomic profiling company that uses next generation sequencing technology ... Scott A. Storrer as chief executive officer. ... he will be responsible for all strategy, business expansion ... , who has served as Strand,s chairman and CEO ...
(Date:7/1/2015)... , July 1, 2015  Axovant Sciences ... focused on the treatment of dementia, today announced ... on July 22 at 5:45 p.m. EDT following ... Alzheimer,s Association International Conference 2015 (AAIC). ... , Dr. Lawrence Friedhoff , ...
(Date:7/1/2015)... ... 2015 , ... A newly launched business plan contest will ask startup companies ... in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small ... period of expert mentorship from a senior industry figure drawn from the Pistoia Alliance ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... Feb. 1 Fears that the economy is not,only ... had,investors in a skittish mood during January. However, biotech ... well ahead of the,NASDAQ, which posted a January loss ... "Healthcare is usually able to ride out extremely volatile ...
... 1 Taligen Therapeutics, Inc. today,announced it anticipates ... Series B,financing. The financing was led by Alta ... including Sanderling Ventures, Tango,and High Country Venture., ... infusion of capital but the,addition of two world ...
... DIEGO, Feb. 1 Cardium Therapeutics (Amex:,CXM) ... million registered direct,offering with institutional and other ... on January 31, 2008. Empire Asset Management,Company ... the transaction., (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ), ...
Cached Biology Technology:January Market Jitters Fails to Derail Biotech 2January Market Jitters Fails to Derail Biotech 3January Market Jitters Fails to Derail Biotech 4Taligen Therapeutics Secures Series B Financing 2Cardium Completes $5.3 Million Registered Direct Offering 2Cardium Completes $5.3 Million Registered Direct Offering 3Cardium Completes $5.3 Million Registered Direct Offering 4
(Date:6/17/2015)... Deutschland und GERMANTOWN, Maryland , June ... ®   Produktlinie mit DNA-Tests verbessert den ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) hat ... STR-Testkits der Produktlinie Investigator ® ... Markt eingeführt. Die neuen Kits zur Erstellung genetischer Fingerabdrücke ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
(Date:6/16/2015)... 16, 2015 Fingerprint Cards has received ... in the company,s portfolio from one of its module partners ... mainly take place during the third quarter 2015. The sensors ... . Jörgen Lantto, CEO of FPC, comments: ...   growing interest from smartphone OEMs in integrating touch fingerprint ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2
... in Colombia,s Cerrejn coal mine by researchers from the Smithsonian ... Natural History helps to explain the origin of one of ... Cerrejonemys wayuunaiki takes its genus name from Cerrejn, ... spoken by the Wayuu people who live on the Guajira ...
... if you are making cellulosic ethanol, you want less lignin ... are using pyrolytic methods, you want more lignin because lignin ... or minimize lignin content, an understanding of lignin synthesis is ... adaptation to life on land, as it strengthens plant cell ...
... through which it can protect itself against newly-developing cancer ... in our organs every day. Once tumours have developed, ... from the immune system. Scientists from the research group ... (HZI) in Braunschweig have now succeeded to reveal a ...
Cached Biology News:Convergent evolution in lignin biosynthesis: Tools for re-engineering biomass composition 2The immune system's guard against cancer 2The immune system's guard against cancer 3